Silke Wedekind Satellitensymposium „Beyond Clinical Trials in B-Cell Malignancies: What Real World Experience Tells Us" anlässlich des 24. Kongresses der Euro- pean Hematology Association (EHA); Amsterdam, Niederlande, 13. Juni 2019; Veranstalter: Gilead Nichtresezierbares hepatozelluläres ...
(NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second ...
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016;137:1742–50.e4 32. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz- Arnau A et al. Omalizumab for the treatment of chronic idiopathic ...
We found a significant effect of group, F(2,101)=20.333, p<0.001, η2=0.291. We followed this up with Bonferroni corrected post-hoc tests, which revealed that the WS group and the VSMA controls were both significantly less accurate than the VMA controls (p<0.001), but not significantly...
In der neuen S3-Leitlinie „Diagnostik und Therapie des hepatozellulären Karzinoms und biliärer Karzinome“ wurde die Leitlinie des hepatozellulären Karzinoms (HCC) umfassend überarbeitet und erstmals um die biliären Karzinomen ergänzt. In den letzten Jahren wurden viele Studien zur...